Catalyst Pharmaceuticals (CPRX) Cash from Investing Activities (2011 - 2026)

Catalyst Pharmaceuticals' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$27000.0 for Q1 2026.

• Quarterly Cash from Investing Activities changed N/A year-over-year to -$27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85000.0 (up 76.19% YoY) and the FY2025 annual result came in at -$58000.0, up 89.57% from the prior year.
• Cash from Investing Activities was -$27000.0 for Q1 2026 at Catalyst Pharmaceuticals, up from -$32000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$10000.0 in Q2 2024 and bottomed at -$162.4 million in Q1 2023.
• A 5-year average of -$26.8 million and a median of -$132000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 70215.91% — and 2024, when it jumped 99.88%.
• Catalyst Pharmaceuticals' Cash from Investing Activities stood at -$132000.0 in 2022, then slumped by 28928.79% to -$38.3 million in 2023, then jumped by 99.77% to -$88000.0 in 2024, then soared by 63.64% to -$32000.0 in 2025, then increased by 15.62% to -$27000.0 in 2026.
• Business Quant data shows CPRX's Cash from Investing Activities at -$27000.0 in Q1 2026, -$32000.0 in Q4 2025, and -$26000.0 in Q2 2025.